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Available online 27 July 2016N-acetyltransferase 2 (NAT2) catalyzes the acetylation of isoniazid to N-acetylisoniazid. NAT2 polymorphism ex-
plains 88% of isoniazid clearance variability in adults. We examined the effects of clinical and genetic factors on
Michaelis-Menten reaction kinetic constants of maximum velocity (Vmax) and afﬁnity (Km) in children 0–
10 years old. We measured the rates of isoniazid elimination and N-acetylisoniazid production in the blood of
30 children. Since maturation effects could be non-linear, we utilized a pharmacometric approach and the artiﬁ-
cial intelligence method, multivariate adaptive regression splines (MARS), to identify factors predicting NAT2
Vmax and Km by examining clinical, genetic, and laboratory factors in toto. Isoniazid concentration predicted
both Vmax and Km and superseded the contribution of NAT2 genotype. Age non-linearlymodiﬁed theNAT2 geno-
type contribution until maturation at ≥5.3 years. Thus, enzyme efﬁciency was constrained by substrate concen-
tration, genes, and age. Since MARS output is in the form of basis functions and equations, it allows multiscale
systemsmodeling from the level of cellular chemical reactions to whole body physiological parameters, by auto-
matic selection of signiﬁcant predictors by the algorithm.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Isoniazid is a ﬁrst line antituberculosis agent recommended for
treatment of children with tuberculosis (TB). Its conversion is catalyzed
by arylamineN-acetyltransferase (NAT) isoenzyme 2 (NAT2) in phase II
xenobiotic metabolism. NAT2 is central to detoxifying many environ-
mental-, industrial-, and food-based arylamines and hydrazines. NAT2
catalyzes the reaction of acetyl-CoA and isoniazid (substrates) to pro-
duce CoA andN-acetylisoniazid.NAT2 single nucleotide polymorphisms
(SNPs) identiﬁed in adults led to classiﬁcation of individuals as slow and
rapid acetylators. Speciﬁc SNPs could be associated with changes in en-
zyme catalytic activity, as deﬁned by enzyme reaction kinetic constants
in liver tissue (Blum et al., 1991; Fretland et al., 2001). The elimination
of isoniazid from the body is a combination of NAT2metabolism and di-
rect elimination of parent compound, with parent isoniazid elimination
in urine of up to 37%. However, in adult patients 88% of systemic clear-
ance variability has been linked to NAT2 SNPs (Kinzig-Schippers et al.,ses Research and Experimental
Dallas, TX 75204, USA.
. Gumbo).
. This is an open access article under2005). While the ontogeny of phase I enzymes is well established, the
age-dependent maturation changes in phase II enzymes such as NAT2
are still poorly understood. This is important since isoniazid peak con-
centrations and 0–24 h area under the concentration-time curves
(AUC0–24) are major determinants of cure rates, speed of sterilizing ef-
fect, and acquired drug-resistance, in TB patients (Chigutsa et al.,
2015; Pasipanodya et al., 2013, 2012; Pasipanodya and Gumbo, 2011;
Gumbo et al., 2014; Dheda et al., 2014). There could be an age-depen-
dent difference in systemic clearance of isoniazid in children, however,
the effect of maturation, or other pediatric factors, on NAT2 enzyme ki-
netics has hitherto not been investigated (Jeena et al., 2011; Rey et al.,
2001). Here, we identiﬁed the rate of production of N-acetylisoniazid
and the rate of elimination of isoniazid in children enrolled in the pro-
spective PHATISA study (Hiruy et al., 2015) and investigated the possi-
ble effects of NAT2 SNPs, measures of body-size, age, and nutrition
status, in altering NAT2 reaction kinetics and isoniazid elimination
rate constants.
Human growth and physiological maturation are non-linear pro-
cesses, with discordant changes that have direct effect on drug pharma-
cokinetics (Kearns et al., 2003). Indeed, in recent years it has become
evident that even in adults the relationships between differentthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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are not only non-linear, but have high order interactions, with data
zones of discontinuity in the relationships (Hall et al., 2011, 2013;
Jain et al., 2013). Thus, standard statistical analyses could be limited
on several fronts, including reliance on linear analyses and the re-
strictive normality, collinearity and sampling assumptions needed
for valid inference. In 2012, Kiser et al. used standard statistical and
pharmacokinetic approaches and identiﬁed that NAT2 genotype
and child's age were associated with isoniazid clearance in South Af-
rican infants. With the slow acetylator genotype, weight adjusted
clearance was unchanged from week 0 to week 12 but increased
28% in week 84; while for rapid acetylators it increased 13% from
week 0 to week 12 but then decreased by 23% in week 84 (Kiser et al.,
2012). In other words, the changes were non-linear. Isoniazid elimina-
tion is from a combination of NAT2metabolism and loss of parent com-
pound in urine, which could account for the complex picture observed.
Here, we used non-linear science to identify the role of maturation,
weight, and NAT2 SNPs on xenobiotic metabolism in children
(Campbell, 1987; Campbell et al., 1985; Dokoumetzidis et al., 2002).
We applied artiﬁcial intelligence (AI)-based non-linear analyses to in-
vestigate NAT2 maximum velocity (Vmax) and afﬁnity (Km) during the
ﬁrst decade of life in children with TB. We were interested in determin-
ing relationships that could be used to scale from the level of enzyme-
based chemical reactions to the whole organism (patient) in the clinic,
to allow for direct translation.
Machine learning is a branch of AI-based methods that we have ap-
plied to examine pathophysiological and clinical parameters as well as
therapeutic outcomes in the past, whereby it outperformed standard
statistical inference with datasets of as little as 28 patients (Chigutsa
et al., 2015; Gumbo et al., 2014; Modongo et al., 2015, 2016; Jain et al.,
2013; Pasipanodya et al., 2013, 2015). One method, multivariate adap-
tive regression splines (MARS), was introduced by Friedman (1991).
MARS has been utilized by several groups for a variety of purposes,
with both large and small clinical sample sizes for a larger number of
predictors (Brasier et al., 2012; George and Chang, 2014; Lee et al.,
2014; Lin et al., 2008; Liu et al., 2015; Ju et al., 2014). Studies included
examination of concentrations of 8 proteins as potential predictors in
30 patients for helicobacter infection, RNA-sequencing data to differen-
tiate genes with low and high expression in the entire human genome
from sample sizes as low as four per group, and an examination of 419
plasma protein concentrations as potential predictors of dengue fever
in 55 patients. MARS uses an optimization procedure that employs
basis functions (BF) to examine candidates for both main and interac-
tion effects in a piecewise manner. BFs are ﬂexible mathematical linear
spline functions that describe relationship between variables in short
segments of dataspace, which allows ﬁt of both nonlinear and linear re-
lationships as well as their interactions simultaneously. A backward
elimination step is used to select a set of BFs that minimizes mean-
square errors, after which multifold cross validation procedure is
employed for model validation. The general cross-validation (GCV)
step gives ameasure of howwell themodelwill performon an indepen-
dent dataset. In AI, an interaction is encountered when one predictor
modiﬁes another predictor's effect on the outcome (say Vmax). In the
same model, MARS identiﬁes inﬂection thresholds (termed “hinges”),
where relationship between predictor and target changes or even
ceases to exist within speciﬁc and well-deﬁned data-space. This essen-
tially allows the slope of the relationship between target and predictor
to be different for different data ranges of the same predictor variable,
and allows for discontinuity of relationships in some data spaces. Final-
ly, the variable importance score is used for ranking and selecting pre-
dictors, especially important when the number of predictors is
relatively large compared to the number of observations (as was the
case in our study) and when many of the predictors could be co-linear
(Breiman, 2001). Here, we applied MARS to data obtained from an ex-
perimental clinical design to identify predictors of NAT2 Vmax and Km
in South African children with TB.The philosophy and purpose of AImethods such asMARS differ from
standard statistical inferences (Breiman, 2001; Hastie et al., 2009). The
underlying scientiﬁc philosophy in standard statistical inference is re-
jection of a pre-speciﬁed null hypothesis. Comparison of distributions
and the measures of central tendency (or hazard rates) between two
or more groups are often the main way to test hypotheses, with tests
of signiﬁcance designed to make sure that differences observed are
not due to chance. The purpose of MARS is not for hypothesis testing,
but rather for hypothesis generation. Since these algorithms are distri-
bution free, measures of central tendency are not the issue. Moreover,
MARS algorithm uses non-parametric regression: in other words, pre-
dictors do not take a pre-speciﬁed form but are derived from the data.
The main objective of MARS is prediction and pattern recognition,
based on present data. Thus, there is no test of signiﬁcance. Rather, the
algorithms determine how likely the prediction is likely to be true
with different datasets. During the GCV-step, the algorithms randomly
split the dataset into different sized smaller sets and calculate a GCV
score, which tells us how well predictors will perform on an entirely
new data-set. When predictors and their interactions are identiﬁed
with these approaches, they becomehypotheses to be tested using stan-
dard statistical inference.
2. Methods
2.1. PHATISA Study Design
The study design, regulatory approvals, and the summary pharma-
cokinetic parameter results of the PHATISA study have been published
in the past (Hiruy et al., 2015). Clinical and demographic factors were
recorded. Malnutrition was measured using Z scores for height-for-
age, weight-for-age, and weight-for-height, and mid-upper arm cir-
cumference (MUAC), since it has been proposed that isoniazid elimina-
tion could be affected by malnutrition. The nutrition measures such as
MUAC and Z-scores were interpreted based on WHO criteria (http://
whqlibdoc.who.int/hq/1997/WHO_NUT_97.4.pdf). The children had
blood draws after directly observed therapy between the fourth and
twelfth day after initiation of anti-TB therapy. In order maximize exper-
imental design and limit the number of samples drawn, and to reduce
the number of children under study, times for blood draw were specif-
ically identiﬁed using optimal sampling theory (Reed, 1999; Wang and
Endrenyi, 1992).We drew blood for concentration of both isoniazid and
its metabolite, N-acetylisoniazid at 0, 0.42, 1.76, 3.37, 10.31 and 24 h
after an isoniazid dose. Blood was processed for extraction of isoniazid
and N-acetylisoniazid, as well as for DNA extraction.
2.2. Isoniazid and N-acetylisoniazid Concentration Measurement Assays
N-acetylisoniazid was synthesized from isoniazid standard using
acetic anhydride and a previously published method. Following sample
preparation using an acetonitrile-based protein precipitation process,
measurement of drug and metabolite concentrations was carried out
by liquid chromatography-tandem mass spectrometry on an AB Sciex
5500 Q-trap mass spectrometer coupled to an Agilent 1200 UPLC sys-
tem. An Exterra 2.1 mm × 50 mm C18 column and a mobile phase of
water with 0.1% formic acid at a ﬂow rate of 200 μL/min was used for
separation. The mass spectrometer was operated in the positive ion
mode and the following transitions monitored: Isoniazid:
138.1 → 51.9 and 138.1 → 66, N-acetyl isoniazid: 180 → 66 and
180 → 78.6 and 6-aminonicotinic acid (internal control): 138.7 → 51
Analyst® 1.5 software version 1.5.1 was used for quantitation.
2.3. NAT2 Genotyping
DNAwas extracted from buffy coats using the Qiagen Flexigene DNA
Kit. The entire NAT2 gene was ampliﬁed by PCR using the sense primer
(5′ GAC ATT GAA GCA TAT TTT GAA AG 3′) and the antisense primer (5′
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1991). Ampliﬁcation conditions were as follows: an initial denaturation
of 5min at 95 °C, followed by 35 cycles of denaturation at 95 °C for 30 s;
annealing at 55 °C for 30 s; extension at 72 °C for 60 s, with a ﬁnal exten-
sion of 5min at 72 °C. Sanger sequencing (performed by Inqaba Biotech-
nical Industries) was used to determine NAT2 genotypes. NAT2 alleles
were characterized by polymorphisms located at seven positions 191,
282, 341, 481, 590, 803, and 857, as described by the Database of
arylamine N-acetyltransferases (NATs) (http://nat.mbg.duth.gr;
McDonagh et al., 2014; Sabbagh et al., 2011). SNPs at these 7 positions
have a genotype/acetylation status prediction of accuracy of 98.4%
(Cascorbi et al., 1995; Hein and Doll, 2012).
2.4. Identiﬁcation of Enzyme Kinetics and Pharmacokinetic Parameter
Estimates
We implemented two types of models from the ADAPT software of
D'Argenio et al. (2009). The parameter estimates for each child were es-
timated using the maximum-likelihood solution via the expectation-
maximization algorithm (MLEM). The changes in concentration of iso-
niazid (INH) and N-acetylisoniazid (ANIH) with time were utilized in
two types of pharmacometric models. The ﬁrst was a pharmacokinetic
model for the plasma concentrations of parent drug and its metabolite,
with no assumptions of NAT2 saturability. The isoniazid elimination rate
(KINH) aswell as the fraction of isoniazidmetabolized (fINH) and the vol-
ume of distribution of metabolite VAINHwere used to calculate the elim-
ination ratio VAINH/fINH. In order to identify NAT2 Vmax (mg/h) and Km
(mg/L) for isoniazid metabolism in each child, we co-modeled the con-
centration versus timeof isoniazid andN-acetylisoniazid using a 2-com-
partment model, chosen based on our prior work with this drug (Hiruy
et al., 2015; Pasipanodya et al., 2013). A standard two-stage estimation
methodwas used to generate initial Km and Vmax values and other phar-
macokinetic parameter estimates. The parameters identiﬁed were then
used in subroutine POPINIT of ADAPT, and enzyme reaction kinetic con-
stants and pharmacokinetic parameter estimates for each child were
then identiﬁed using MLEM.
2.5. Frequentist Statistical Analysis
We employed the D'Agostino and Pearson omnibus normality test
and a p-value N0.05 for normality tests. Comparison between propor-
tions was made using the Fischer's exact or χ-square tests. Comparison
betweenmedians or means made via the Kruskal-Wallis test. All statis-
tical testing other than machine learning methods were performed
using STATA version 13 software (STATA Software, College Station,
Texas).
2.6. Machine Learning
MARS uses BFs to examine candidates for both main and interaction
effects, which gives MARS ﬂexible and adaptive capabilities to ﬁt non-
linear and linear relationships and interaction components simulta-
neously. Over ﬁtting procedures were used to grow large models with
up to 15 BFs, which were then pruned back using GCV function during
the backward pass. Each variable was assigned a measure of predictive
importance byMARS, entailing bothmarginal and interaction effects in-
volving this variable. We examined for predictors of four target pheno-
typic responses: Vmax, Km, KINH and VAINH/fINH. The potential predictors
entered for each model for each of the four responses were each child's
NAT2 genotype, age in days, INH dose, observed peak concentration, HIV
status, gender, height, weight, body mass index (BMI) in kg/m2, Z-
scores for both height and weight, as well as MUAC. The coefﬁcient of
determination (R2) values, variable importance measures and the
MARS equation for selected models are reported. All machine learning
modeling was performed on the SPM Salford Predictive Modeler® soft-
ware suite version 7.0 (SALFORD Software, San Diego, California).Except for setting maximum allowable basis functions to 15, all other
settings were set to default for both the exploratory legacy mode and
in cross-validation.
3. Results
We enrolled children ≤ 10 years old who presented with TB to King
Edward VIII Hospital in Durban, South Africa, between May 2012 and
March 2013.We enrolled 19 boys and 11 girls, whose clinical character-
istics are shown in Fig. 1. The ﬁgure shows that most children were one
year-old or less. All children had chest X rays performed, 19 (63%) had
consolidation and 4 (13%) had cavitation, thus most children had pul-
monary TB. Fig. 2 shows Z-scores and demonstrates that up to 30% of
children were malnourished, though only one was severely malnour-
ished (Z-score standard deviation b−3).
Isoniazid acetylation follows a ping-pong Bi-Bi mechanism de-
scribed by the standard Michaelis-Menten relationship for enzyme
rate reaction rate (v) and substrate concentration [S] (Michaelis and
Menten, 1913; Weber and Cohen, 1968):
v ¼ V max  S½ = Km þ S½ ð Þ ð1Þ
We generated Km and Vmax values for each child in ADAPT based on
this relationship, with estimates shown in Fig. 3A–B. The mean popula-
tion estimate for Kmwas 1.69 mg/L, which translates to 0.012 μM,while
that of Vmax was 30.11 mg/h, which translates to 0.06 μM/s. Fig. 3A-B
show that Km was tightly distributed around the mean, but there was
greater variability in the Vmax. The isoniazid elimination rate (KINH) is
shown in Fig. 3C. Fig. 3D shows the elimination ratio VAINH/fINH, calculat-
ed using the fraction of isoniazid metabolized (fINH), and the volume of
distribution of metabolite VAINH.
NAT2 sequencing results, including the base pairs and SNP calls for
each allele, are shown in Extended Dataset 1. We identiﬁed 17 different
alleles, including four reference high-activity NAT2*4 alleles. The most
frequent genotypes were NAT2*5B/NAT2*5B encountered in 6/30 (20%)
children, and NAT2*5C/NAT2*12C encountered in 6/30 (20%) children;
the former genotype is commonly reported in literature to confer slow
acetylator status, while the latter is predicted to confer the intermediate
acetylator status (McDonagh et al., 2014). On the other hand, homozy-
gosity for the rapid acetylator NAT2*4 reference allele (NAT2*4/NAT2*4
genotype) was encountered in 2/30 (7%) of enrolled children (Table 1).
As a ﬁrst step, we employed standard frequentist statistics to com-
pare the distributions of Km, Vmax, and elimination rate between differ-
ent inferred genotypes and predicted acetylation status. Table 2 shows
no signiﬁcant differences in mean values. Compared the distributions
of the same enzyme function parameters, as well as measures of body
size, age, and dose by inferred acetylator status, shown in Table 2. The
only statistically signiﬁcantﬁndingwas that the isoniazid dose adminis-
tered was lower among rapid acetylators.
Next, we used MARS algorithm in order to identify predictors of
Vmax. Table 3 shows that dose (BF1), genotype (BF5), isoniazid peak con-
centration (BF7), and age (BF10) were identiﬁed as the best predictors of
Vmax. The table illustrates the nature of MARS output, which is the form
of basis functions (BF). BF1 is a simple hinge function “max (0, Dose–
190)” which means that the value of the expression is zero for all
doses (mg) up to 190 (i.e., for all doses satisfying “Dose minus 190”
less than zero), as illustrated in Fig. 4A. The dose of 190 mg is at the
hinge. The variable importance score of 100% means that “Dose” is the
most important variable for Vmax. Isoniazid peak concentration was
also an important predictor (BF7), with a variable importance score of
90%, very close to that of “Dose”; thus both dose and peak concentration
likely reﬂect the same thing, which is effect of isoniazid concentration
on Vmax. BF7 means that isoniazid concentration had no effect on Vmax
until the peak concentration achieved the threshold value of 8.83 mg/
L, at the hinge. Table 3 shows that the peak concentration (BF7)
interacted with BF5 (genotype). However, the BF5 interaction with BF7
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Fig. 1.Demographic and dosing characteristics in 30 children. The p-values shown in each graph are for the D'Agostino and Pearson omnibus normality test. A p-value N 0.05 is signiﬁcant,
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there is staggered or stratiﬁed effect so that relationship applied to some
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that were grouped by MARS, which had a variable importance score of
90%, similar to that of isoniazid concentration. Of note, for MARS analy-
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Fig. 3.N-acetyltransferase enzyme kinetic and isoniazid elimination constants in children with tuberculosis. Mean values with (±) standard deviations for all 30 children. (A). Maximum
velocity (mg/h) value distribution (B). Afﬁnity (mg/L). (C). Isoniazid elimination rate constant (per hour). (D). Elimination ratio distribution.
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cade. Overall, the relation between Vmax and these four predictors was
given by the equation:
Vmax mg=hrð Þ ¼ 31:297þ 0:030BF1−1:025BF7−0:001BF10;R2
¼ 0:89 ð2Þ
Thus, age (maturation) affects speed of isoniazid acetylation by
modifying effect of genotype, a non-linear interaction, however after
5.3 years the maturation is complete.
Table 4 shows the BFs for NAT2 afﬁnity for isoniazid, or Km. A child's
height was the primary predictor and had the highest variable impor-
tance score. Height however could be substituted by age, given the
tight link between height and age (Pearson r = 0.917; p b 0.001), a
tightly linked relationship frequently used in the clinic. Thus age was
themain predictor of Km aswell; in fact, the coefﬁcient of determination
(R2) value of age alone was 31%. However, MARS also identiﬁed thatTable 1
List of NAT2 genotypes and different phenotypes in 30 tuberculosis children.
NAT2 Genotype Inferred acetylation status
Number of children
Isoniazid pha
Isoniazid elim
*4/*4 Rapid 2 10.306 (0.00
*4/*5C Intermediate 1 10.307
*4/*14E Intermediate 2 10.306 (0.00
*5B/*5B Slow 6 10.311 (0.01
*5B/*5C Slow 2 10.308 (0.01
*5C/*5K Slow 1 10.306
*5C/*6N Slow 2 10.308 (0.00
*5C/*11A Intermediate 1 10.320
*5C/*12A Intermediate 1 10.308
*5C/*12C Intermediate 6 10.311 (0.01
*5C/*14E Slow 1 10.309
*5D/*11A Intermediate 1 10.311
*6A/*12A Intermediate 1 10.301
*6B/*6B Slow 1 10.304
*12A/*12B Rapid 1 10.292
*12A/*13A Rapid 1 10.317isoniazid peak concentration and genotype as important predictors
(Table 4). Combined, these factors explained 80% of the variance in
NAT2 enzyme afﬁnity, as given by equation for Km and its predictors:
Km mg=Lð Þ ¼ 1:721−0:001BF1 þ 0:044BF2−0:001BF4
þ 0:045BF6;R2
¼ 0:80 ð3Þ
Table 4 shows that BF4 is a special type of a basis function, described
by an interaction of BF1 (age or height) and genotype. In other words,
age constrained the effect of genotype on enzyme afﬁnity.
Table 5 shows the BFs for isoniazid elimination constant (KINH). The
elimination rate constant is a composite measure reﬂecting both acety-
lation and elimination of parent compound via loss in urine. The main
predictors were isoniazid dose and NAT2 genotype. In this case, howev-
er BF2was an interaction based on themodiﬁcation of effect of genotype
on the effect of isoniazid dose (i.e., isoniazid concentration), an examplermacokinetic parameter estimates NAT2 enzyme function
ination rate (KINH) Maximum velocity (Vmax) Afﬁnity (Km)
6) 30.460 (0.335) 1.678 (0.010)
28.797 1.716
3) 29.919 (1.733) 1.699 (0.049)
6) 29.563 (3.679) 1.717 (0.067)
8) 30.349 (0.608) 1.687 (0.018)
29.640 1.699
6) 30.802 (1.578) 1.677 (0.043)
30.198 1.687
29.823 1.700
2) 30.233 (1.395) 1.683
30.163 1.690
30.864 1.670
30.864 1.670
28.231 1.758
31.690 1.652
31.881 1.646
Table 2
Distribution of demographic characteristics and measures of NAT2 enzyme function between inferred acetylation status groups.
Inferred acetylation status
Rapid (n = 3) Intermediate (n = 13) Slow (n = 14) P-valuea
Enzyme function
Isoniazid elimination 10.301 (0.010) 10.310 (0.010) 10.308 (0.012) 0.2945
Maximum velocity (Vmax) 30.870 (0.749) 30.206 (1.234) 29.853 (2.422) 0.273
Enzyme afﬁnity (Km) 1.669 (0.017) 1.686 (0.028) 1.704 (0.049) 0.2122
Demographic characteristics
Age-in-days 1131.5 (867.3) 1151.4 (942.5) 1064.76 (1094.61) 0.7297
Weight (kg) 12.67 (5.13) 12.83 (5.25) 12.06 (6.01) 0.8655
Height (cm) 90 (18.35) 90.54 (16.68) 85.14 (20.85) 0.6456
Body mass index (kg/m2) 15.20 (2.29) 15.25 (2.65) 15.95 (4.04) 0.9462
Isoniazid dose (mg/kg) 6.29 (1.98) 15.80 (4.40) 11.39 (5.22) 0.099
Isoniazid total daily dose (mg) 73.33 (15.28) 147.69 (41.06) 130.71 (102.37) 0.017
a Based on K-Wallis test.
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in Eq. (4):
KINH ¼ 10:297þ 0:0003BF1−0:0002BF2;R2 ¼ 0:64 ð4Þ
This was conﬁrmed by standard regression methods, which showed
that for each unit increase in isoniazid dose above 40mg, KINH increased
by an additional 2.82 × 10−4 per hour for subset 1 versus 1.05 × 10−4
per hour for subset 2 genotypes, a 2.69-fold change in slope.
As regards to the ratio VAINH/fAINH, the R2 for the relationship was
only 0.55 in the best model. We thus considered that our potential pre-
dictors such as clinical and demographic factorswere not as explanatory
of this parameter, and thus no further explorations were made.
4. Discussion
In pharmacometrics, primary pharmacokinetic parameters are the
observed values such as elimination rate constant (KINH), volume of dis-
tribution (both central and peripheral), and in the current study also Km
and Vmax. These observations quantify rates and extents of underlying
physicochemical processes. In other words, these parameters, including
the enzyme reaction constants, are the biological phenotypes. On the
other hand, in pharmacogenomics, inferred acetylation status is com-
monly termed the “acetylation phenotype.” Acetylation phenotype is a
grouping of drug clearances (into 3 overlapping Gaussian curves).
Moreover, commonly in clinical practice, acetylation status is assigned
using 2-h post-dose isoniazid concentrations. However, the isoniazid
elimination rate itself is a product of at least two physicochemical pro-
cesses, acetylation and the loss of unmetabolised (parent) compound
in urine. “Phenotyping” methods such as the 2-h concentration or con-
centration-time proﬁles or AUC0–24 are even further removed from the
primary process of N-acetylation: they are products of several primary
biological processes, namely absorption rate constant (and closely relat-
ed time to maximum concentration), volume of distribution, and elim-
ination rate constants. Only the last of these is related to acetylation, and
only partially. The primary biological process of acetylation itself (i.e.,
the phenotype), sensu strictiore, is deﬁned by Km and Vmax values,
which are the “observed” values based on calculations using the
Michaelis-Menten Eq. (1). These values are thus not inferred fromTable 3
Factors predictive of maximal velocity (Vmax) on MARS analysis.
Function
BF1 max (0, Dose−190)
BF5 Genotype subset 1
BF7 max (0, Peak isoniazid concentration−8.83)*BF5
BF10 max (0, 1934.5-Age)
NAT2 genotype subset #1: 5D/*11A, 5C/12C, 5C/*14E, *4/*4, *4/*5, *4/*5C, *5B/*5B, *5C/*12A, *5C/*genotypes, but are the “observed”. Thus, effect of genotype should be in-
ferred based on these phenotypes, and not vice-versa. Here, we simply
asked: what are the physiological and clinical factors that could affect
these quantitativemeasures of phenotype, if at all, andwhich factors af-
fect them the most? In terms of the genes, what groupings of NAT2
genes categorize the phenotypes of isoniazid NAT2 afﬁnity and maxi-
mum velocity in children, during periods of highest growth? MARS, in
which predictors do not take a pre-speciﬁed form or groupings (e.g. in-
ferred acetylation status), is excellent at such an agnostic function, and
utilizes only the presented data for its own categorization.
To answer these questions, we identiﬁed the Km and Vmax values for
each child from clinical data, based on a pharmacometric approach. The
meanpopulation estimates of 0.012 μMforKm for isoniazid. In biochem-
ical assays for measurement of Km that examined isoniazid acetylation
by human NAT2 from 2-h post-mortem liver homogenates of a rapid
acetylator in the laboratory, the Km values were 0.018 ± 0.004 μM
(Weber and Cohen, 1968). This means that the pharmacometric ap-
proach of using the rate of production of N-acetylisoniazid and disap-
pearance of isoniazid is a robust enough approach to calculate these
values for each child, and gives values similar to those from enzyme ki-
netic experiments of liver biopsy specimens. In other words, the mea-
surement of the phenotype was likely accurate. In the case of the
NAT2 alleles we identiﬁed in the children, genotypes such as NAT2∗4,
NAT2∗12A, NAT2∗12B, NAT2∗12C, and NAT2∗13 alleles, and the predomi-
nance of the NAT2*5 allele have been shown to be common in Black
South African adults (Dandara et al., 2003; Loktionov et al., 2002).
Thus, the distribution of the common alleles in our small pediatric co-
hort mirrors that in adults. Application of AI methods to these parame-
ter estimates and genotypes identiﬁed several important patterns
between the predictors and enzyme reaction kinetic constants. Our ap-
proach is tractable and follows steps that are easy to apply to any pedi-
atric drug whose metabolite is known for each child, and for a
population of children. Thus, our approach could be used to examine
the effects of maturation and drug doses on both compartmental phar-
macokinetic parameters and Michaelis-Menten relationships for other
phase II metabolism reactions, an unexplored pediatric space (Kearns
et al., 2003).
Second, a current problem in systems pharmacology is the difﬁculty
in scaling mathematical models from the level of chemical reactionsUnits Variable importance score (%)
Dose in mg 100
Allele 1/Allele 2 90
mg/L 90
Age in days 42
5K, *6B/*6B.
Fig. 4. Contribution of dose and age onmaximum velocity. (A). Effect of dose on Vmax, shows lack of effect of dose below 190mg, after which dose has a positive relationship with Vmax. In
this case, dose is a surrogate of drug concentration. (B). Theﬁgure summarizes thehinge function “max (0, 1934.5-Age)”, a perfect example of theﬂexibility ofMARS inmodeling change in
relationship between predictor and outcome at a hinge, and thus non-linear. The ﬁgure shows that there is a large effect of age until 5.3 years when the contribution gets to a plateau,
suggesting the point of full maturation.
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patients. The MARS equations output could allow this to be accom-
plished, starting with reaction kinetics at the level of a Michaelis-
Menten reaction to whole body physiological parameters in the child
(isoniazid elimination rate), based on relevant clinical and demographic
predictors automatically selected by the algorithm. Moreover, MARS
handles both linear and non-linear interactions simultaneously,
allowing for construction of non-linear models. Furthermore, MARS is
assumption anddistribution free and isﬂexible enough to identify inter-
actions without a prior falsiﬁable hypothesis to link reactions constants
to a predictor, as is the case of isoniazid concentration and Km. The ﬁnd-
ings led to newhypotheses being generated,which can nowbe tested in
separate studies using standard statistical approaches. Thus, themathe-
matical relationships are identiﬁed ﬁrst, and then physiological mean-
ings can be investigated further to improve the precision of the
estimates for better reproducibility.
Third, we found that the relationships between predictors such as
age, dose or isoniazid concentration, and NAT2 enzyme kinetics were
non-linear. In other words, several clinical and physiological factors af-
fected speed of isoniazid acetylation and afﬁnity, and interacted with
each other. Of major importance was the effect of age on both speed
of acetylation and enzyme afﬁnity. Age played a critical role inmodulat-
ing these enzyme activities, and age's contribution changedwith child's
age, with themaximal adult type of activity encountered after 5.3 years
old. This time period likely reﬂects the time to maturation of the NAT2
enzyme. On theother hand, the effect of dose anddrug concentration al-
ways superseded that of NAT2 genotype. The effect of dose and drug
concentration was persistent regardless of the enzyme reaction con-
stant examined, and was often the primary predictor, except in the
case of Km. The physiological and pharmacological basis for this remain
to be worked out, but the fact that the hinge was always encountered
beyond a certain concentration suggests a real concentration-depen-
dent effect, consistent with many pharmacological processes. The GCV
step identiﬁed R2 ≥ 80% on post-test sets, which means there is a high
likelihood of the same observations with future data-sets, so that theTable 4
Factors predictive of enzyme afﬁnity (Km) on MARS analysis.
Function
BF1 max (0, height-54)
BF2 Max (0, isoniazid peak concentration-11.7)
BF4 Genotypes subset 1*BF1
BF7 Genotypes in subset 2
NAT2 genotype subset 1: *5D/*11A, *5C/*12C, *4/*14, *4/*5, *4/*5C, *5B/*5B, *5B/*5C, *5C/*5K, *5C/
NAT2 genotype subset 2: *12A/*13A, *6A/*12A, *4/*4.ﬁndings are likely valid. However, clearly nothing in our current under-
standing of Km and Vmax can explain how the pharmacological and clin-
ical factors we identiﬁed as predictors could affect both enzyme afﬁnity
andmaximumvelocity for isoniazid acetylation. However, the historical
disaster of gray baby syndrome in children treated with the drug chlor-
amphenicol suggests that maturation has a major effect on enzyme
function (Glazer et al., 1980; Mulhall et al., 1983; Sutherland, 1959).
The functional deﬁciency in the UDP-glucuronyl transferase enzyme
system encountered in the ﬁrst few weeks of life, especially in prema-
ture neonates, led to cardiovascular collapse when high concentrations
of the antibiotic were achieved in the children (Glazer et al., 1980;
Mulhall et al., 1983; Sutherland, 1959). However, we reiterate that,
the philosophy behindmachine learningmethods such as MARS is pre-
diction and pattern recognition, and not identiﬁcation of causal path-
ways. Thus, the next step is to test the effect of age and isoniazid
concentration on NAT2 Km and Vmax using standard hypothesis testing
approaches, and if conﬁrmed then a new understanding of NAT2 cata-
lyzed reaction kinetics should be sought.
Fourth, ourﬁndings could impact themostwidely used pharmacoki-
netic models of maturation as commonly recommended by regulatory
authorities (European Medicines Agency, 2007). Several methods are
used to examine the effect of maturation on pharmacokinetic parame-
ters, with the two most common being allometric scaling based on the
¾ fractal geometry law and physiologically-based pharmacokinetic
modeling (Hope et al., 2007). Thesemethods use speciﬁc drug clearance
rates derived in adults to estimate drug clearances in children, with on-
togeny effects scaled based on dry tissue weight of the organ clearing
the drug. The central assumption is that xenobiotic metabolism enzyme
reaction rates are the same between adults and children, and that what
varies is the quantity of the enzymes proportional to organ weight and
size. It is recognized in some cases, as for example sirolimus, that there
could be different fetal isoform enzymes that get replaced by others
after birth, thereby leading to altered clearance (Emoto et al., 2015);
nevertheless the reaction kinetic constants of each of the different iso-
forms are assumed ﬁxed. Moreover, the development of clearanceUnits Variable importance score (%)
centimeters 100
mg/L 53
Allele 1/Allele 2 26
Allele 1/Allele 2 26
*6N.
Table 5
Factors predictive of isoniazid elimination rate constant.
Function Units Variable importance score (%)
BF1 max (0, Dose−40) mg 100
BF2 Genotypes subset 1*BF1 Allele 1/Allele 2 19
NAT2 genotype subset 1: *5C/*12A, *12A/*13A, *5C/*12/, *5C/*14E, *5C/*12A, *5C/*6N, *6B/
*6B.
NAT2 genotype subset 2: *5C/*11A, *12A/*12B, *6A/*12A, *4/*4, *4/*5, *4/*5C, *5B/*5B, *5B/
*5C, *5C/*5K.
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data suggests that non-linear functions and analyses,with no a priori as-
sumptions, could be more accurate.
Finally, we found no quantitative relationship between severalmea-
sures of malnutrition such as Z-scores and isoniazid metabolism. In-
deed, no single model included Z-scores and MUAC as a predictor.
However, most children had moderate malnutrition, and it could be
that effects are encountered only with severe malnutrition. Thus, this
question remains unresolved.
Our study has several limitations. The ﬁrst is the small number of
children enrolled. However, we deliberately optimized experimental
design to identify information rich pharmacokinetic sampling so that
the smaller numbers were deliberate. Moreover, MARS has successfully
identiﬁed predictors in smaller populations than these ones in several
studies by us and by others. Second, our ﬁndings lack physiological ex-
planations. Thesewill be subject of future studies. Third, the intent of AI
approaches we used is not hypothesis testing, but rather pattern recog-
nition. Thus, future studies in which our ﬁndings are tested as a falsiﬁ-
able hypothesis are recommended.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.ebiom.2016.07.031.
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